NASDAQ:ASMB - Assembly Biosciences Stock Price, Forecast & News

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Assembly Biosciences Inc (NASDAQ:ASMB) issued its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.93) by $0.03. The biopharmaceutical company earned $4.23 million during the quarter, compared to analyst estimates of $3.45 million. Assembly Biosciences had a negative net margin of 647.72% and a negative return on equity of 52.83%. View Assembly Biosciences' Earnings History.

Assembly Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Assembly Biosciences.

4 equities research analysts have issued twelve-month target prices for Assembly Biosciences' stock. Their forecasts range from $20.00 to $74.00. On average, they anticipate Assembly Biosciences' share price to reach $41.33 in the next year. This suggests a possible upside of 94.7% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.

Media stories about ASMB stock have been trending very negative on Sunday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Assembly Biosciences earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Assembly Biosciences.

Assembly Biosciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,310,000 shares, an increase of 8.5% from the January 15th total of 2,130,000 shares. Based on an average daily volume of 599,700 shares, the days-to-cover ratio is presently 3.9 days. Approximately 9.8% of the company's shares are short sold. View Assembly Biosciences' Current Options Chain.

Some companies that are related to Assembly Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Tandem Diabetes Care (TNDM), Arbutus Biopharma (ABUS), FibroGen (FGEN), Inovio Pharmaceuticals (INO) and Lexicon Pharmaceuticals (LXRX).

Assembly Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (9.17%), Jennison Associates LLC (9.01%), Victory Capital Management Inc. (5.14%), Victory Capital Management Inc. (5.09%), Franklin Resources Inc. (2.78%) and FMR LLC (2.75%). Company insiders that own Assembly Biosciences stock include Derek A Small, Jacqueline Sybil Papkoff, Richard James Colonno, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.

ASMB stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Oxford Asset Management LLP, Prudential Financial Inc., Russell Investments Group Ltd., AXA, Sectoral Asset Management Inc, Goldman Sachs Group Inc. and Bank of America Corp DE. Company insiders that have sold Assembly Biosciences company stock in the last year include Jacqueline Sybil Papkoff and Richard James Colonno. View Insider Buying and Selling for Assembly Biosciences.

ASMB stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Victory Capital Management Inc., Victory Capital Management Inc., Franklin Resources Inc., FMR LLC, Marshall Wace North America L.P., Bain Capital Public Equity Management II LLC and Bailard Inc.. View Insider Buying and Selling for Assembly Biosciences.

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ASMB stock can currently be purchased for approximately $21.23.

Assembly Biosciences has a market capitalization of $553.04 million and generates $14.80 million in revenue each year. The biopharmaceutical company earns $-90,750,000.00 in net income (profit) each year or ($3.98) on an earnings per share basis. Assembly Biosciences employs 95 workers across the globe.View Additional Information About Assembly Biosciences.

The official website for Assembly Biosciences is http://www.assemblybio.com/.

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]